Ask VialBase
Review / Perspective · PMID 41948476

Obesity Pharmacotherapy Reimagined: The Era of Multi-Receptor Agonists and Next-Generation Metabolic Modulators — VialBase Research

Multi-receptor agonists (dual and triple) represent a paradigm shift in obesity treatment

Last updated · 2026 · Lempesis IG, Dalamaga M · Metabolism Open
Key findings
  • Multi-receptor agonists (dual and triple) represent a paradigm shift in obesity treatment
  • Retatrutide positioned as leading triple agonist candidate
  • Obesity projected to affect two-thirds of adults globally by 2050
  • Beyond incretin-based therapies: amylin analogs, activin receptor inhibitors, and combination approaches emerging
  • Controversies around long-term safety, lean mass loss, and access/cost remain

Summary

This 2026 review from Harvard Medical School and the University of Athens provides a comprehensive overview of the multi-receptor agonist era in obesity pharmacotherapy. It contextualizes retatrutide within the broader landscape of next-generation metabolic modulators, from dual agonists (Tirzepatide) to triple agonists (retatrutide) to entirely novel mechanisms.

Key Findings

  • Obesity affects over 2 billion adults globally, with projections indicating nearly two-thirds of adults affected by 2050
  • Evolution of incretin therapy: single (GLP-1) → dual (GIP/GLP-1) → triple (GIP/GLP-1/glucagon)
  • Each added receptor provides incremental efficacy: ~15% → ~22% → ~24% weight loss
  • Retatrutide’s glucagon component adds:
    • Direct hepatic fat oxidation
    • Increased energy expenditure
    • Enhanced lipolysis
    • But also risk of lean mass loss and glycemic destabilization
  • Emerging next-gen approaches beyond incretin agonists:
    • Amylin analogs (cagrilintide + semaglutide = CagriSema)
    • Activin receptor II inhibitors (bimagrumab — addressing lean mass loss)
    • Oral GLP-1 RAs at higher doses
    • Combination therapies
  • Unresolved controversies: lean mass loss (~40% of weight lost), bone density effects, weight regain after discontinuation, cost/access equity, long-term safety beyond 2-3 years

Relevance to Retatrutide

This review provides essential context for positioning retatrutide in the obesity drug landscape. It highlights retatrutide as the frontrunner among triple agonists while honestly addressing the controversies — particularly lean mass loss (potentially worse with glucagon component) and the need for long-term safety data. The review also points toward the next generation of therapies that may complement or succeed incretin agonists, which is relevant for understanding retatrutide’s competitive position. Also relevant to Semaglutide and Tirzepatide.

Citation

Lempesis IG, Dalamaga M. Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies. Metabol Open. 2026;30:100463. doi:10.1016/j.metop.2026.100463.

See Also

View on PubMed · PMID 41948476 →